Search Results - "Rocha Lima, C M"

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial by Weiss, J.M., Csoszi, T., Maglakelidze, M., Hoyer, R.J., Beck, J.T., Domine Gomez, M., Lowczak, A., Aljumaily, R., Rocha Lima, C.M., Boccia, R.V., Hanna, W., Nikolinakos, P., Chiu, V.K., Owonikoko, T.K., Schuster, S.R., Hussein, M.A., Richards, D.A., Sawrycki, P., Bulat, I., Hamm, J.T., Hart, L.L., Adler, S., Antal, J.M., Lai, A.Y., Sorrentino, J.A., Yang, Z., Malik, R.K., Morris, S.R., Roberts, P.J., Dragnev, K.H.

“…Chemotherapy-induced damage of hematopoietic stem and progenitor cells (HSPC) causes multi-lineage myelosuppression. Trilaciclib is an intravenous CDK4/6…”
Get full text

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer by Kindler, H.L., Richards, D.A., Garbo, L.E., Garon, E.B., Stephenson, J.J., Rocha-Lima, C.M., Safran, H., Chan, D., Kocs, D.M., Galimi, F., McGreivy, J., Bray, S.L., Hei, Y., Feigal, E.G., Loh, E., Fuchs, C.S.

“…We evaluated the efficacy and safety of ganitumab (a mAb antagonist of insulin-like growth factor 1 receptor) or conatumumab (a mAb agonist of human death…”
Get full text

A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma by Marsh, Robert de W, Rocha Lima, C M, Levy, D E, Mitchell, E P, Rowland, Jr, K M, Benson, 3rd, A B

“…Perifosine, a heterocyclic alkylphosphocholine signal transduction inhibitor, has activity against multiple cell types in vitro. This is a phase II study to…”
Get full text

Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902 by Rocha-Lima, C.M., Herndon, J.E., Lee, M.E., Atkins, J.N., Mauer, A., Vokes, E., Green, M.R.

“…Background: This phase II study evaluated the efficacy and safety of the irinotecan/gemcitabine combination in patients with relapsed/refractory small-cell…”
Get full text

Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer by Wolpin, B.M., O'Reilly, E.M., Ko, Y.J., Blaszkowsky, L.S., Rarick, M., Rocha-Lima, C.M., Ritch, P., Chan, E., Spratlin, J., Macarulla, T., McWhirter, E., Pezet, D., Lichinitser, M., Roman, L., Hartford, A., Morrison, K., Jackson, L., Vincent, M., Reyno, L., Hidalgo, M.

“…We evaluated AGS-1C4D4, a fully human monoclonal antibody to prostate stem cell antigen (PSCA), with gemcitabine in a randomized, phase II study of metastatic…”
Get full text

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy by Garrett, C R, Siu, L L, El-Khoueiry, A, Buter, J, Rocha-Lima, C M, Marshall, J, LoRusso, P, Major, P, Chemidlin, J, Mokliatchouk, O, Velasquez, L, Hayes, W, Feltquate, D, Syed, S, Ford, S, Kollia, G, Galbraith, S, Nuyten, D S A

“…Background: The objectives of this phase I study were to determine the safety, pharmacokinetics (PK), pharmacodynamics and efficacy of brivanib combined with…”
Get full text

Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC by Rocha Lima, C. M., Rizvi, N. A., Zhang, C., Herndon, J. E., Crawford, J., Govindan, R., King, G. W., Green, M. R.

“…Background: To evaluate the activity and tolerability of gemcitabine plus irinotecan or docetaxel as first-line chemotherapy for advanced non-small cell lung…”
Get full text

Irinotecan Plus Gemcitabine Induces Both Radiographic and CA 19-9 Tumor Marker Responses in Patients With Previously Untreated Advanced Pancreatic Cancer by Rocha Lima, C. M. S.

Get full text

Leishmania infantum infection rate in dogs housed in open-admission shelters is higher than of domiciled dogs in an endemic area of canine visceral leishmaniasis. Epidemiological implications by Estevam, Letícia G.T.M., Veloso, Laura B., Silva, Geralda G., Mori, Carina C., Franco, Paula F., Lima, Ana C.V.M. Rocha, Ássimos, Gabriela R., Reis, Ilka A., Andrade-Filho, José D., Araújo, Márcio S.S., Ribeiro, Vitor M., Almeida, Ana P.M.M., Paz, Gustavo F.

“…•Among 627 dogs housed in open-admission shelters, 211 (33.6%) were seropositive for canine visceral leishmaniasis.•PCR-RFLP of 118 seropositive animals…”
Get full text

Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines by Bahadori, H R, Rocha Lima, C M, Green, M R, Safa, A R

“…Gemcitabine (2'-2'-difluorodeoxycytidine, dFdC), an analog of deoxycytidine, is an antineoplastic agent with clinical activity against several types of cancer…”
Get more information

Naturally infected Lutzomyia sand flies in a Leishmania-endemic area of Brazil by Carvalho, Gustavo M L, Andrade Filho, Jose D, Falcao, Alda L, Rocha Lima, Ana C V M, Gontijo, Celia M F

“…In Brazil, Leishmania transmission involves several species of phlebotomine sand flies that are closely associated with different parasites and reservoirs,…”
Get more information

Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer by Rocha Lima, C M, Eckardt, J R, Leong, S S, Sherman, C A, Perkel, J A, Putman, T, Safa, A R, Bahadori, H R, Green, M R

“…Gemcitabine is a fluoridated pyrimidine related to cytosine arabinoside that has significant activity in solid tumor models. Irinotecan is a camptothecin…”
Get more information

EUS-FNA with rescue FISH for the diagnosis of pancreatic carcinoma in patients with inconclusive on-site cytopathology by Akunyili, I. I., Rocha Lima, C. M. S., Macintyre, J., Solis, N., Merchan, J. R., Sleeman, D., Levi, J. U., Ribeiro, A.

“…Abstract only…”
Get full text

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial by Weiss, J M, Csoszi, T, Maglakelidze, M, Hoyer, R J, Beck, J T, Domine Gomez, M, Lowczak, A, Aljumaily, R, Rocha Lima, C M, Boccia, R V, Hanna, W, Nikolinakos, P, Chiu, V K, Owonikoko, T K, Schuster, S R, Hussein, M A, Richards, D A, Sawrycki, P, Bulat, I, Hamm, J T, Hart, L L, Adler, S, Antal, J M, Lai, A Y, Sorrentino, J A, Yang, Z, Malik, R K, Morris, S R, Roberts, P J, Dragnev, K H

“…Chemotherapy-induced damage of hematopoietic stem and progenitor cells (HSPC) causes multi-lineage myelosuppression. Trilaciclib is an intravenous CDK4/6…”
Get full text

Phase I trial of weekly and every 3 weeks ixabepilone (Ix) and sunitinib (S) in advanced solid tumors (STs) by Kittaneh, M., Montero, A. J., Kovacs, K., Guardiola Amado, V. D., Flores, A. M., Ferrell, A., Vulfovich, M., Pegram, M. D., Benedetto, P. W., Rocha Lima, C. M. S., Merchan, J. R.

“…Abstract only…”
Get full text

Combination study of navitoclax with gemcitabine (G) in patients (pts) with solid tumors by Cleary, J. M., Rocha Lima, C. M. S., Hurwitz, H., Montero, A. J., Shapiro, G., Franklin, C., Yang, J., Graham, A. M., Busman, T., Mabry, M., Holen, K. D., Krivoshik, A., Humerickhouse, R., Uronis, H.

“…Abstract only…”
Get full text

Global, multicenter, open-label, randomized phase II trial comparing gemcitabine (G) with. G plus AGS-1C4D4 (A) in patients (pts) with metastatic pancreatic cancer (mPC) by Wolpin, B. M., O'Reilly, E. M., Ko, Y., Blaszkowsky, L. S., Rarick, M. U., Rocha Lima, C. M. S., Ritch, P. S., Chan, E., Spratlin, J. L., Macarulla, T., McWhirter, E., Pezet, D., Lichinitser, M., Roman, L. D., Hartford, A., Jackson, L., Vincent, M., Reyno, L. M., Hidalgo, M.

“…Abstract only…”
Get full text

Does delay of adjuvant chemotherapy affect the clinical outcome in patients with colon cancer? by Bayraktar, U. D., Bayraktar, S., Herna, S., Ku, N., Jones, C., Merchan, J., Sands, L. R., Marchetti, F., Montero, A., Rocha-Lima, C. M.

“…Abstract only 4046 Background: Adjuvant chemotherapy (AC) in patients with stage III colon adenocarcinoma prevents recurrences and improves survival. Although…”
Get full text

Gemcitabine and oxaliplatin (GEMOX), a promissing combination for the treatment of relapsed, advanced or metastatic non small cell lung cancer (NSCLC) by Calfa, C. J., Raez, L. E., Lopes, G., Walker, G., Farfan, N., Macintyre, J., Blaya, M., Rocha-Lima, C. M.

“…Abstract only…”
Get full text

A phase I study of brivanib alaninate (BMS-582664), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full dose cetuximab (BC) in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy by Garrett, C. R., Siu, L. L., El-Khoueiry, A. B., Buter, J., Rocha-Lima, C. M., Marshall, J. L., Kollia, G., Velasquez, L., Syed, S., Feltquate, D.

“…Abstract only…”
Get full text